Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
J. Craig Venter
AddedFeb 13, 2024
UpdatedMay 31, 2026
J. Craig Venter

J. Craig Venter

Founder, Human Genome Sciences

Crunchbase

J. Craig Venter's Career

Human Genome Sciences
Human Genome Sciences

Rockville, MD, US

Founder
Agradis
Agradis

Los Angeles, CA, US

Board Member· Board
Viridos
Viridos

Los Angeles, CA, US

Co-Founder
Human Longevity
Human Longevity

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

J. Craig Venter's Career

Human Genome Sciences
Human Genome Sciences
Acquired01992Rockville, MD, US
Founder

Leadership at Human Genome Sciences

Colin GoddardColin GoddardBoard Member
Jerry KarabelasJerry KarabelasBoard Member
Allan BaxterAllan BaxterBoard Member

Similar to Human Genome Sciences

GSKGSKLondon, Greater London, GBBiotech, Pharmaceuticalsest. 2000GSKLondon, Greater London, GB · est. 2000

GSK PLC: A British multinational firm innovating in pharmaceuticals, biotech, and health products.

Public · $25.5M69.4k
GeneDx HoldingsGeneDx HoldingsStamford, CT, USGenetic Testingest. 2017GeneDx HoldingsStamford, CT, US · est. 2017

Connecticut-based GeneDx, a software company merging diagnostics and data science for personalized health insights.

Public · $941M919
Agradis
Agradis
Series A$24M10k2011Los Angeles, CA, US
Board Member· Board

Leadership at Agradis

Alfonso RomoAlfonso RomoCo-Founder
Alejandro RodriguezAlejandro RodriguezCEO
Alfonso Romo GarzaAlfonso Romo GarzaBoard Member

Similar to Agradis

Targeted GrowthTargeted GrowthSeattle, WA, USCrop Enhancementest. 1998Targeted GrowthSeattle, WA, US · est. 1998

Targeted Growth, Inc.: A crop-biotech firm innovating yield-enhanced products.

Pre-Seed · $44.4M19
AgrageneAgrageneSan Diego, CA, USPest Controlest. 2017AgrageneSan Diego, CA, US · est. 2017

Agragene, a sustainable agri-tech firm, uses advanced genome engineering for eco-friendly pest control, enhancing global crop quality & productivity.

Series A · $5.2M6
AgSmartsAgSmartsMemphis, TN, USAgricultural Technologyest. 2014AgSmartsMemphis, TN, US · est. 2014

AgSmart Inc.: A US-based agricultural biotech firm offering automation consulting, crop data analysis, and irrigation management.

Angel · $1.1M5
AgrynexAgrynexIthaca, NY, USBiopesticides, Crop Protectionest. 2015AgrynexIthaca, NY, US · est. 2015

Agrynex: Providing biocidal enzymes for crop protection against soil-borne diseases.

Angel · $50k4
Viridos
Viridos
Series A$202M7502005Los Angeles, CA, US
Co-Founder

Leadership at Viridos

Juan EnriquezJuan EnriquezCo-Founder
Reinhard AmbrosReinhard AmbrosBoard Member
Hamilton SmithHamilton SmithCo-Founder
David C. KiernanDavid C. KiernanBoard Member

Similar to Viridos

Wild MicrobesWild MicrobesCambridge, MA, USSustainable Productsest. 2022Wild MicrobesCambridge, MA, US · est. 2022

Wild Microbes: Innovating sustainable products through advanced microbial technology.

Pre-Seed · $3.3M4
Yali BioYali BioSouth San Francisco, CA, USFood, Ingredientsest. 2021Yali BioSouth San Francisco, CA, US · est. 2021

Yali Bio: Using synthetic biology for sustainable, climate-smart food production and deforestation mitigation.

Seed · $3.9M16
Vir BiotechnologyVir BiotechnologySan Francisco, CA, USMedicines, Therapeuticsest. 2016Vir BiotechnologySan Francisco, CA, US · est. 2016

Vir Biotechnology, a clinical-stage firm, develops and commercializes treatments for viral and bacterial diseases in California.

Public · $908.6M576
VirogenomicsVirogenomicsPortland, OR, USBiotech Consultingest. 2001VirogenomicsPortland, OR, US · est. 2001

Virogenomics BioDevelopment, based in Portland, aids in transitioning early-stage biotech innovations from labs to market, ensuring maximum impact.

Pre-Seed · $587.4k30
Human Longevity
Human Longevity
Acquired$340.5M02013San Diego, CA, US
Board Member· Board

Leadership at Human Longevity

Richard ScheuermannRichard ScheuermannBoard Member
Robert HaririRobert HaririBoard Member
David KarowDavid KarowCEO
Max FoxMax FoxBoard Member
Bryan JohnsonBryan JohnsonBoard Member
Peter DiamandisPeter DiamandisBoard Member

J. Craig Venter's Similar Executives & Operators

WILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiJaeHong ChoiJaeHong ChoiBoard Member · KakaoKim Beom-sooKim Beom-sooCo-Founder · KakaoMason YeoMason YeoBoard Member · KakaoBrian KimBrian KimCo-Founder · KakaoSean JohSean JohBoard Member · KakaoBrian KimBrian KimBoard Member · Kakao

People Similar to J. Craig Venter

John MasonJohn MasonCo-Founder · CeleraJim CollinsJim CollinsCo-Founder · Sherlock BiosciencesGreg CritchfieldGreg CritchfieldBoard Member · Sera PrognosticsCraig C TaylorCraig C TaylorCo-Founder · Alloy VenturesCraig OverpeckCraig OverpeckCEO · Bioinformatics